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Claudin-1Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths, worldwide. MicroRNAs,
inhibiting gene expression by targeting various transcripts, are involved in genomic dysregulation during
hepatocellular tumorigenesis. In previous studies, microRNA-198 (miR-198) was shown to be signiﬁcantly
downregulated in HCV-positive hepatocellular carcinoma (HCC). Herein, the function of miR-198 in hepato-
cellular carcinoma cell growth and gene expression was studied.
In hepatoma cell-types with low levels of liver-speciﬁc transcription factor HNF1α indicating a low differen-
tiation grade, miR-198 expression was most downregulated. However, miR-198 treatment did not restore the
expression of the liver-speciﬁc transcription factors HNF1α or HNF4α. Importantly, overexpression of
miR-198 in Pop10 hepatoma cells markedly reduced cell growth. In agreement, comprehensive gene
expression proﬁling by microarray hybridisation and real-time quantiﬁcation revealed that central signal
transducers of proliferation pathways were downregulated by miR-198. In contrast, genes mediating cellular
adherence were highly upregulated by miR-198. Thus, the low expression of E-cadherin and claudin-1, in-
volved in cell adhesion and cell-cell contacts, was abolished in hepatoma cells after miR-198 overexpression.
This deﬁnite induction of both proteins by miR-198 was shown to be accompanied by a signiﬁcantly impaired
migration activity of hepatoma Pop10 cells.
In conclusion, miR-198 acts as a tumor suppressor by repression of mitogenic and motogenic pathways
diminishing cell growth and migration.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is a primary liver cancer that is the
ﬁfth most common cancer, leading to nearly 600,000 deaths a year,
worldwide. Hepatitis B and C infections are frequent causes for HCC
development. Other risk factors like aﬂatoxin B1, excessive alcohol
abuse, drugs, hemochromatosis, and obesity play also an important
role in development and progression of HCC [1–3].niversity Hospital of Cologne,
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thal).
l rights reserved.Development of HCC is a multistep process, in which nearly 80% of
HCC cases evolve from liver cirrhosis [2–5]. During progression of
HCC, chromosomal and genetic alterations as well as epigenetic
abnormalities can result in cellular dysfunction [3,5,6]. Chromosomal
and epigenetic disarray leads to HCC progression by affecting the
main proliferative cellular pathways [3,6,7]. Hepatocyte growth factor/
hepatocyte growth factor receptor (HGF/MET) is affected by point
mutations leading to a constitutive expression or overexpression. The
insulin like growth factor IGF-2 mediates its high mitogenic potential
by activation of the phosphatidylinositol 3-kinase (PI3K) and protein
kinase B (AKT/PKB), in addition to Raf/mitogen activated protein kinase
(MAPK) pathways [3,4,7,8]. In response to IGF-2 signaling, transcrip-
tional upregulation of vascular epidermal growth factor (VEGF), and
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proliferation and angiogenesis of the tumor. In addition, the HGF/MET
pathway, a key mitogenic and motogenic pathway responsible for he-
patic cell proliferation, is dysregulated during hepatocarcinogenesis
[9–11].
In addition to the chromosomal and epigenetic alterations, genetic
dysregulation of essential signaling pathways is orchestrated by
tumor suppressor and oncogenic microRNAs. MicroRNAs (miRNAs)
are small, non-coding RNA molecules that regulate gene expression
on the post-transcriptional level by binding to and inhibiting target
transcripts. During hepatocarcinogenesis, a wide variety of miRNA
are dysregulated [12–15]. Thus, recent ﬁndings have shown that
miR-21, miR-221 and miR-222 are increased in HCC [16,17]. miR-21
is a highly potent inhibitor of expression of many tumor suppressor
proteins such as the phosphatase and tensin homolog (PTEN) protein
and is thereby an enhancer of cell proliferation and migration [16].
Similarly, both miR-221 and miR-222 are strongly increased in HCC.
Their overexpression results in reduced apoptosis and altered cell
cycle control by targeting expression of many cell cycle associated
proteins [18,19]. However, most miRNA species are downregulated
during hepatocarcinogenesis [13,20]. miR-122 is the most abundant
miRNA in liver and composes about 70% of all miRNA in hepatocytes
[21]. Most reports have shown that miR-122 is strongly down-
regulated in HCC [22,23]. Loss of miR-122 affects hepatic metabolism,
in particular the synthesis of cholesterol [24] and also cell cycle
regulation [23]. In addition, miR-101, miR-145, and miR-199b
are miRNAs which are downregulated after hepatocarcinogenesis
[12,25].
In previous studies, we have demonstrated that miR-198 is one of
the most prominently downregulated miRNA in HCC. Interestingly,
the decrease of miR-198 was linked to the degree of liver injury and
hepatocarcinogenesis [20]. miR-198 is moderately diminished in
livers with cirrhosis, but even more so after development of dysplas-
tic foci and after progression of HCC [20]. Furthermore, Cheung et al.
have observed that miR-198 is decreased in liver tissues of patients
with non-alcoholic fatty liver disease (NAFLD) [26]. Sung et al. identi-
ﬁed miR-198 as a regulator of cyclin T [27] and, importantly, Tan et al.
described that miR-198 targets the expression of the HGF receptor,
Met, in Huh-7 hepatoma cells [28].
In the present study, we analyzed the impact of miR-198 on signal-
ing pathways in hepatoma cells. Here, we demonstrate that over-
expression of miR-198 in hepatoma cells leads to a marked inhibition
of cell growth and cell migration. Comprehensive expression proﬁling
in response to miR-198 underlines its crucial role in hepatocellular
carcinogenesis, pointing to a dysregulation of immune responsive sig-
naling, but most notably to central mitogenic andmotogenic pathways.
2. Material and methods
2.1. Cell culture and transfection of miRNA
Human hepatoma cells Huh-7 [29], Hep3B [30], and Pop10 [31]
were maintained in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplemented with 10% fetal calf serum (FCS) in 5% CO2 at 37 °C in
humidiﬁed atmosphere. For transfection with miRNA, 3×105 cells
were seeded on each well of a 6-well plate and transfected with ei-
ther scrambled RNA [50 nM], miR-198 mimic [50 nM], or siRNA
against HNF1α [10 nM] (caggacaagcatggtcccaca), HNF4α [10 nM]
(aacctagagattgttacagaa), E-cadherin [30 nM] (tttgactgtaatcacacca
tctgtg), or claudin-1 [10 nM] (gcatcctcctgggagtgatagcaat) from Ther-
mo Scientiﬁc Dharmacon (Bonn, Germany) using lipofectamine
2000 (Invitrogen, Karlsruhe, Germany) according to the instructions
of the manufacturer. Four hours after transfection, the medium was
changed and cells were maintained in DMEM supplemented with
10% FCS for 24 h. Finally, cells were harvested for protein or RNA
isolation.2.2. Determination of cell growth, proliferation, and apoptosis
For analyses of cell viability, 24 h after transfection of Pop-10
hepatoma cells were treated with reagents of the Cell Titer 96 Aqueous
One Solution Cell Proliferation Assay (Promega, Mannheim, Germany)
according to the manufacturer. Cell viability was the measured at a
wavelength λ=450 nM as recommended by the contractor.
Apoptosis of transfected hepatoma cells was analyzed by the
TUNEL assay using the In Situ Cell Death Detection Kit from Roche
Applied Science (Mannheim, Germany) following the manufacturer's
instructions. Apoptotic cells were quantiﬁed by counting ﬂuorescent
nuclei.
Cell proliferation was measured 24 h after miR-198 transfection of
Pop-10 hepatoma cells by application of the ClickiT-Edu-Proliferation
Kit (Invitrogen, Grand Island, NY, USA) due to the manufacturer's in-
structions. Detection of cell proliferation was performed by visual
counting of ﬂuorescence positive cells using the cell^P software
(Olympus Europe Holding GmbH, Hamburg, Germany).
2.3. Determination of cell migration
For examination of the inﬂuence of miR-198 on cell migration,
hepatoma cells were transfected with 50 nM scrambled RNA or
miR-198 mimic. After 24 h, cell monolayers were scratched and mon-
itored within 24 h. In addition, the Boyden chamber system was used
for migration detection. 7×104 cells were seeded on the transwells
(6.5 mm) with 8 μm pores (Corning B.V. Life Sciences, Amsterdam,
The Netherlands). During seeding, cells were transfected either with
50 nM scrambled RNA or miR-198 in DMEM containing 2% FCS.
Analyses of cell migration were performed after hematoxylin staining
by light microscopy using the cell^P software for statistical evaluation
(Olympus Europe Holding GmbH).
2.4. Total RNA isolation
Total RNAwas isolated using Qiazol reagent following the instructions
of themanufacturer (Qiagen, Hilden, Germany). RNA quantity was deter-
mined by the ND-1000 NanoDrop spectrophotometer (NanoDrop,
Wilmington, DE, USA) and RNA quality was analyzed by microcapillary
electrophoresis using the nanoRNA chip (2100 BioAnalyser, Agilent
Technologies, Waldbronn, Germany).
2.5. Transcript and miRNA quantiﬁcation by real-time PCR
Total RNA (1 μg) was reverse transcribed and polyadenylated using
the miScript reverse transcription kit (Qiagen) as instructed. 10 ng
cDNA was then applied for real-time PCR using Power SYBR Green
PCR MasterMix (Applied Biosystems Life Technologies, Darmstadt,
Germany) and transcript speciﬁc primer sets (Supplemental Table 1).
For quantiﬁcation of miRNA levels, 2 ng cDNA was applied for real-
time PCR, using speciﬁc miScript Primer Assays from Qiagen. All
reactions were performed in triplicates.
mRNA transcripts were normalized to hypoxanthin-phosphoribosyl-
transferase (HPRT) transcript levels. For normalization of the miRNA
levels RNU6B was used as reference. Transcript and miRNA levels were
calculated by the ΔΔCt-method. Primer used for quantiﬁcation and
validation analyses are listed in Supplemental Table 1.
2.6. Expression proﬁling by microarray hybridization
For gene expression proﬁling, hepatoma Pop10 cells were trans-
fected with either 50 nM scrambled RNA or miR-198 for 24 h. Total
RNA quantity and quality wasmonitored bymicrocapillary electropho-
resis (2100 BioAnalyser, Agilent Technologies, Waldbronn, Germany).
RNA samples of 300 ng and a RIN≥9 were reverse transcribed,
followed by an in vitro transcription. Samples were chemically linked
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(Affymetrix, Santa Clara, CA, USA). All cell experiments for gene
expression proﬁling were performed in triplicates.Fig. 1. miR-198 impact on HNF1α and HNF4α expression in different hepatoma cell types
different hepatoma cells of Hep3B, Huh-7, and Pop10 cell lines was quantiﬁed by real-time
(D). After treatment with miR-198, protein levels of HNF1α and HNF4αwere analyzed byW
with scrambled RNA or miR-198. Actin protein levels were used for normalization (E). HNF1
(siHNF1alpha, siHNF4alpha) [10 nM] for 24 h. Quantiﬁcation of HNF1α, HNF4α, and miR-
levels were indicated by relative units [RU] (A–G).Hybridization arrays were scanned with the GeneChip Scanner
3000 7 G, controlled by GeneChip Operating Software (GCOS,
Affymetrix). Raw data was processed with the Robust Multiarray. Expression of miR-198, HNF1α, and HNF4α in normal liver parenchyma (PC) and in
PCR (A, B, C). miR-198 transfection in Pop10 cells resulted in increased miR-198 levels
estern blotting in Huh-7 and Pop10 cells, either untreated (negative control) or treated
α and HNF4αwere knocked down in Huh7 (F) and in Pop10 cells (G) by speciﬁc siRNA
198 expression levels were performed by real-time PCR (F, G). miRNA and transcript
1193N. Elﬁmova et al. / Biochimica et Biophysica Acta 1833 (2013) 1190–1198Average (RMA) algorithm, then variance stabilized and transformed
to a logarithmic scale.
Differences in gene expression were statistically analyzed by
application of the unpaired Mann–Whitney test. Gene ontology
(GO) was performed with GO-terms with p-value less or equal to
0.05 (enrichment score). In addition, array raw data were analyzed
using the GeneSpring GX (Agilent Technologies) and Partec (Partec,
Saint Luois, MO, USA) software. Expression proﬁles involved in cer-
tain pathways were indicated by BioCarta, KEGG, and GenMapp.
2.7. Western blot analysis
Cells were lysed with RIPA buffer containing protease inhibitors
(10 μg/ml) (Roche Applied Biosystems, Mannheim, Germany). 10 μg
of protein lysates were separated and incubated with anti-claudin
(1:1000) (Cell Signaling, Danvers, MA, USA), anti E-cadherin
(1:1000)(Dako, Hamburg, Germany), or anti-actin (1:2500) (Sigma-
Aldrich Chemie GmbH, Munich, Germany) antibodies. After incubation
with either anti-mouse or anti-rabbit secondary antibodies, both
(1:5000) (Dianova, Hamburg, Germany) signals were detected by
enhanced chemiluminescence and quantiﬁed using a FLUORCHEM
FC2 Alpha Ease (Biozym, Hess. Oldendorf, Germany).
2.8. mRNA quantiﬁcation in human HCC
Total RNA was extracted from 52 formalin ﬁxed and parafﬁn em-
bedded (FFPE) HCV positive HCC tissues as described previously
[20]. For real-time PCR claudin-1 speciﬁc primer sets were designed
(Supplemental Table 1) which produce very short amplicons,
enabling quantitative PCR on RNA of FFPE material. Real-time PCR
was carried out as described in Section 2.5, but for absolute quantiﬁ-
cation a standard curve was applied.
2.9. Statistical analyses
Statistical analyses were performed with SPSS software 17 (Chicago,
IL, USA). Data are reported as means±SEM. Variances were calculated
using ANOVA and, statistical analyseswere performed by Student's t-test.
A value of pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. miR-198 expression in hepatoma cells of certain differentiation stages
Since previous data have shown that miR-198 is predominantly de-
creased during hepatocarcinogenis [20], we ﬁrst studied the ex-
pression levels of miR-198 in different hepatoma cell lines. In Hep3BFig. 2.miR-198 overexpression leads to inhibited cell growth of hepatoma cells. Hepatoma P
viability (A), apoptosis (B), and cell proliferation (C). Cell viability and apoptosis were indica
bled RNA transfection were set to RU=1 (A, B). For all assays, four independent experimenand Huh-7 cells and especially in Pop10 cells, the miR-198 concentra-
tionwas very low in comparison to human parenchymal cells of normal
liver (Fig. 1A). Quasdorff et al. have characterized different hepatoma
cell types by their expression of hepatic metabolizing proteins and the
liver-speciﬁc transcription factors, HNF1α and HNF4α [31]. Low levels
of HNF1α and HNF4α indicate the advanced dedifferentiation of hepa-
tocellular carcinoma cells,mimickingHCC progression [31]. Interesting-
ly, both miR-198 and HNF1α transcripts were lowest in Pop10 cells.
Therefore, the miR-198 expression proﬁles highly corresponded to
HNF1α transcript levels in the different hepatoma cell types
(Fig. 1A-C). In order to show the link of miR-198 and expression of
liver-speciﬁc transcription factors, we compensated the low miR-198
expression in hepatoma cells by transfection of mature miR-198.
miR-198 treatment resulted in a more than 500-fold increase of
miR-198 in Pop10 cells (Fig. 1D). Subsequently, the protein levels of
HNF1α and HNF4α were determined in Huh-7 and Pop10 cells in re-
sponse to miR-198 overexpression. Western blot analysis conﬁrmed
the lower expression of both transcription factors in highly
dedifferentiated Pop10 than in Huh-7 cells. Neither in Pop10 nor in
Huh-7 cells miR-198 treatment did change the protein levels of
HNF1α and HNF4α (Fig. 1E). Interestingly, efﬁcient knockdown of the
liver-speciﬁc transcription factors HNF1α andHNF4α by siRNA resulted
in a deﬁnitive decrease of miR-198 expression level (Fig. 1F and G). In
comparison to the regulation of miR-198 in Huh7 cells (Fig. 1F), in
Pop10 cells miR-198 expression was moderately downregulated after
efﬁcient HNF1α and HNF4α silencing (Fig. 1G). This can be explained
by the fact that Pop10 cells already hardly express miR-198.
3.2. High impact of miR-198 on hepatoma cell growth
Next, we addressed whether miR-198 might act as a tumor suppres-
sor miRNA by affecting hepatoma cell growth. Therefore, we transfected
hepatoma cells with miR-198 and measured cell viability (Fig. 2A), apo-
ptosis (Fig. 2B) and cell proliferation (Fig. 2C). miR-198 treatment
resulted in a marginal reduction of cell viability in Huh-7. In Pop10
cells, however, whose endogenous miR-198 expression was nearly
completely abolished (Fig. 1A), a pronounced decrease of cell viability
of more than 60% was detected after miR-198 overexpression (Fig. 2A).
Analysis of apoptosis by TUNEL assays revealed only a small decrease
in the number of apoptotic hepatoma cells, but a signiﬁcant inhibition
of cell proliferation was shown after miR-198 treatment (Fig. 2C).
3.3. Overexpression of miR-198 results in alteration of central cellular
signaling pathways
After providing evidence that miR-198 acts as a potent tumor
suppressor miRNA by inhibition of hepatoma cell growth, we aimedop10 cells transfected with miR-198 revealed an inhibitive inﬂuence of miR-198 on cell
ted in relative units [RU] and the values of both, cell viability and apoptosis after scram-
ts were performed.
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Therefore, a comprehensive gene expression analysis in Pop10 hepa-
toma cells was carried out by microarray hybridization after miR-198
treatment. Cluster analysis revealed that miR-198 overexpression in-
ﬂuenced a wide range of gene expression proﬁles (Fig. 3A). In total,
expression of 85 genes were signiﬁcantly altered with a fold change
higher than 1.5-fold. 49 genes were upregulated and 36 genesFig. 3. Altered gene expression by miR-198 overexpression. Inﬂuence of miR-198 treatment on
fold change of the expression of most signiﬁcantly dysregulated genes after miR-198 transfecti
(C right; shown in red and orange) were analyzed for their linkage in interacting pathways by
Environmental Health Sci Center) and presented as signaling pathway trees. Highly upregulate
implicated in deep red (C).downregulated (Supplemental Tables 2 and 3). Those genes, that
were most differentially expressed after miR-198 treatment are
summarized in Fig. 3B and ﬁndings were validated by real-time PCR
quantiﬁcation shown in the Fig. 4.
Follistatin-like1 (FSTL1), whose exon sequence harbors the miR-198
gene, was the most reduced gene. In contrast to the interferon-
responsive genes that were induced by miR-198 overexpression, genesgene expression of Pop10 cells was proven by hybridization microarray analysis (A). The
on was demonstrated (B). Downregulated (C left; shown in green) and upregulated genes
the Biorag database (http://www.biorag.org/ provided by the Arizona Cancer Center; SW
d genes cyclin 3D (CCND3) and interferon-stimulated transcription factor-γ (ISGF3G) are
Fig. 4. Validation of selected signiﬁcantly dysregulated genes after miR-198 induction. Expression proﬁles of genes, identiﬁed by microarray analysis as signiﬁcantly dysregulated
after miR-198 overexpression in Pop10 cells, were validated by real-time PCR. For validation further six independent experiments of miR-198 overexpression were performed and
total RNA, isolated from scrambled and miR-198 treated Pop-10 cells, was analyzed. Downregulation of nine genes after miR-198 treatment was proven. The transcript levels were
normalized using HPRT as a reference and indicated in Relative Units [RU].
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(Fig. 3C). Importantly, the differential pathway analysis by BioCarta,
KEGG, andGenMapp showed a highly interactive functional link of signif-
icantly dysregulated genes after miR-198 overexpression (Fig. 3C).
3.4. Dysregulation of miR-198 mediates proliferative and morphogenic
pathways
The function of differentially expressed genes was further investi-
gated by in silico inquest, classifying their role into ﬁve functional pro-
cesses by GO analyses: cell proliferation and apoptosis, cell migration,
metabolism, and gene regulation (Table 1). Thus, some key signal
transducers of cellular activation and proliferation including
phosphoinositol 3-kinase (PI3KCA), the receptor of the highly potent
mitogens IGF-1 and IGF-2, and the antiproliferative growth factors
TGF-β as well as its receptor TGF-β receptor type 1 and 2, conﬁrm
the important role of miR-198 in HCC growth and migration
(Table 1). The signiﬁcant dysregulation of these identiﬁed genes
after miR-198 treatment was veriﬁed by quantitative analysis of tran-
scriptional expression levels, shown in Fig. 4.
3.5. Synthesis of E-cadherin and claudin-1 in hepatocellular carcinoma
depends on miR-198 expression
Since after miR-198 overexpression the tight-junction protein
claudin-1 (CLDN1) encoding gene was one of the most prominentlyupregulated genes identiﬁed by microarray analyses (Fig. 3C, Table 1),
we studied expression of claudin-1 and also of E-cadherin more thor-
oughly. In addition to claudin-1, the cell adherence protein E-cadherin
was selected, because its loss, which is observed during hepatocar-
cinogenesis, is suggested to be an important prerequisite of cancer
progression [32–34].
Compensation of reduced miR-198 levels in hepatoma Pop10 cells
by miR-198 treatment resulted into a more than 4-fold increase of
claudin-1 expression. Furthermore, E-cadherin was also highly up-
regulated in response to miR-198 treatment (Fig. 5B). The marked
upregulation of both claudin-1 and E-cadherin synthesis could also
be shown at the protein level (Fig. 5C).
Next, we studied if the inﬂuence of E-cadherin and claudin-1
could also be observed on a collection of liver samples with different
grades of HCC. Both expression levels were reduced in HCC with low
miR-198 levels (Supplemental Fig. S1). In agreement with our in
vitro-studies, real-time quantiﬁcation of miR-198 and claudin-1 on
RNA extracts from HCV positive HCC biopsies [20] revealed a highly
signiﬁcant correlation of miR-198 with claudin-1 expression levels
(r2Spearman=0.691, p=0.0009) (Supplemental Fig. S1).
The loss of claudin-1 and E-cadherin during HCC development is
suggested to be involved in enhanced invasive activity of hepatocellu-
lar carcinoma cells [32,34,35]. Therefore, we addressed the question,
whether miR-198 induced expression of these proteins leads to
impaired cell migration. For this purpose, we measured migration
activity after scratching monolayers of hepatoma cells, overexpressing
Table 1
Signaling pathways affected by miR-198 overexpression.
Signaling pathway Genesa
Immune response OAS1/2/3; IFI6/6L/T1/T1M/27; IRF9; ISG15; Mx1/2; EPSTI1;
Cell proliferation MET; PIK3CA; IGF1R; STX17;
MAP2K4; MAPK8; SMAD2; CCND3; PPP2R1B;
E2F1; RB1; ARHGAP19;
Apoptosis CASP9; PIK3CA/CB/R3; IGF1R; TGFBR2; BMPR3; FAS;
PPP3CA/R1;
Cell metabolism HMGCL; SLC7A6; SLC2A3; EDEM1; TOMM20; PTPMT1;
Cell migration PIK3CA; TGFBR1/2; BMPR3;
ACTN3; CLDN1; ITGB2; CCND3; ZEB2;
RB1; ARHGAP19
Gene regulation RB1; TBP; SP100; FAS; PML; TAF1/9B; ARNT; DIAPH1;
CARM1; GTF2H1/3;
a Genes, signiﬁcantly dysregulated (p≤0.05) after miR-198 overexpression in hepato-
ma cells, were classiﬁed into cell signaling pathways by Biocarta, KEGG, and GenMAPP.
1196 N. Elﬁmova et al. / Biochimica et Biophysica Acta 1833 (2013) 1190–1198miR-198. The slot distances, that were determined between the edges
of the scratched wounds, demonstrated that migration activity was
efﬁciently inhibited by approximately 75% in hepatoma cells treated
with miR-198 (Fig. 5D, E). The miR-198 inﬂuence on cell migration
could also be proven by the Boyden chamber system (Supplemental
Fig. S2). Treatment of Pop10 hepatoma cells with siRNA against
E-cadherin and claudin-1, resulted in a strong activation of cell motili-
ty. The enhanced migration, induced by E-cadherin and claudin-1 RNA
silencing, was partly abolished by miR-198 overexpression (Supple-
mental Fig. S2).Fig. 5. Claudin-1 and E-cadherin synthesis were highly affected by miR-198 overexpression.
miR-198 on claudin-1 (CLDN1) (A) and E-cadherin (B) expression 24 h after treatment. Up
protein level by Western blotting (C). Migration analyses of hepatoma cells that were scr
The distance between the scratching borders [%] indicated the migration within 24 h (E). Va
four independent experiments were performed.4. Discussion
In the present study, novel evidence is shown that in the liver
miR-198 may act as a potent tumor suppressor miRNA by inhibition
of cell growth and migration. miR-198 is markedly decreased in
non-alcoholic steatohepatitis and especially during HCV related
hepatocarcinogenesis [20,26]. In agreement with our previous ﬁnd-
ings, which demonstrated the loss of miR-198 during progression of
hepatocarcinogenesis [20], miR-198 repression is more pronounced
in hepatocellular carcinoma cell types with an advanced dedifferenti-
ation grade, indicated by low levels of liver-speciﬁc transcription
factors. Although miR-198 seems to be closely associated with the
expression of the liver-speciﬁc transcription factor HNF1α, it does
not affect the expression of HNF1α and HNF4α (Fig. 1).
Compensation of miR-198 expression, which is nearly completely
abolished in Pop10 cells (Fig. 1), leads to a highly efﬁcient retardation
of cell growth. However, concordantly to previous data of Tan et al.,
who describe no effect of miR-198 on HepG2 and Hep3B cell prolifera-
tion [28], inhibition of cell growth by miR-198 was only moderate
when using Huh-7 cells. Since Huh-7 cells are characterized by lower
division rates [29] and higher endogenous miR-198 levels than Pop10
cells (Fig. 1), the inﬂuence of additional miR-198, transfected into
cells, is not as distinctive as in a cell type with low miR-198 levels.
These ﬁndings support the data of Tan et al., who described only a
moderate miR-198 effect on proliferation of HGF stimulated HepG2
and Hep3B expressing miR-198 [28]. Thus, cell division and viability
may directly depend on the endogenous miR-198 concentration andReal-time PCR analyses of miR-198 transfected hepatoma cells indicated a high effect of
regulation of claudin-1 and E-cadherin by miR-198 overexpression was proven at the
atched 24 h posttransfection (D) presented a reduction of cell migration by miR-198.
lues of hepatoma cells transfected with scrambled RNA were set to 100%. For all assays,
Fig. 6. Tumor suppressor activities of miR-198 in healthy liver and hepatocellular carcinoma. In healthy liver, miR-198 is more present than in HCC (1) and inhibits the mitogenic
IGF-1R and Met induced signaling pathways by repression of receptor and PIK3CA signal transducer synthesis (2). Abundant miR-198 expression leads to high claudin-1 and
E-cadherin expression (3). After hepatocarcinogenesis miR-198 is suppressed (1), leading to high expression of mitogenic signal transducers and of the TGF-β receptors R1 and
R2 (2), but to low expression of E-cadherin and claudin-1 (3). Altered expression proﬁles due to low miR-198 expression in hepatocellular carcinoma cells contribute to increased
proliferation and migration.
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scribed to impede cell growth of hepatoma cells such as miR-29c,
miR-145, miR-125b, and miR-199b [25,36,37].
miR-198 regulates hepatoma cell migration in addition to the inhi-
bition of cell growth (Figs. 2 and 5D, E), conﬁrming recent data of Tan
et al., who reported the blockade of HGF-induced motogenic effects on
hepatoma cells by miR-198 [28]. In our study we demonstrate the
impact of miR-198 on hepatocellular migration activity by miR-198
regulation of E-cadherin and claudin-1 (Fig. 5A, B, C). Since miR-198
positively affects the synthesis of both proteins, the miR-198 inﬂuence
might be either indirect or due to posttranscriptional positive regula-
tion by stabilization of the E-cadherin and claudin-1 mRNA by putative
miRNA interaction to the 5′-untranslated region [38].
The decrease of the cell adhesion protein E-cadherin in cancer
cells is mediated by β-catenin after TGF-β exposure. Loss of
E-cadherin from the epithelial cell membrane then results in less
cell adherence and promotion of migration [32–34,39]. Therefore,
the disengaged E-cadherin/miR-198 axis during hepatocarcinogen-
esis is suggested to contribute to enhanced hepatoma cell migration
that in turn leads to increased metastatic activities of HCC.
In addition to E-cadherin, the expression of the tight-junction associ-
ated protein claudin-1 is highly controlled by miR-198 (Fig. 5). The
family of claudins consists of 25 identiﬁed members, all involved in
maintenance of cellular polarity, cell growth, and cell differentiation,
but with different roles in cell migration [40,41]. Claudin-7 decreases
cell migration and invasion in lung cancer [42], but claudin-2 is
found to trigger lung cancer cell migration by induced matrix-
metalloproteinase (MMP)-9 release [43]. Furthermore, claudin-6, 7,
and 9 enhance gastric adenocarcinoma cell migration and invasion
[44]. Yoon et al. have demonstrated that claudin-1 contributes tomigra-
tion [45], but these ﬁndings were not conﬁrmed by Higashi et al. [35].
Claudins are often dysregulated in cancer [41] and claudin-1 was
shown to be signiﬁcantly reduced in HCC. Furthermore, the loss of
claudin-1 is associated with a poor prognosis of HCC [35]. Therefore,
the newly identiﬁed regulation of claudin-1 by miR-198 in this study
is of particular importance, although its function is controversially
discussed.
In addition to claudin-1, we foundmiR-198 mediated dysregulation
of a wide range of signal transducing proteins that take part in cell
motility and cell growth reactions by gene expression proﬁling.
Genes involved in cell growth andmigration were signiﬁcantly affectedby miR-198 (Table 1; Fig. 3). Thus, we recognized by bioinformatic
analyses, highly potent mitogenic mediators such as IGF-1 receptor
and the catalytic subunit of phosphoinositol-3-kinase (PIK3CA), but
also both receptors of TGF-β. Interestingly, by increasing the miR-200
expression and downregulating the Zeb-1 and Zeb-2 proteins (data
not shown), miR-198 seems also to be involved in the TGF-β/ZEB/
miR-200 signaling network that is known to regulate tumor cell inva-
sion by E-cadherin expression [46]. Whereas stimulated IGF-2 signaling
is mainly described as a malignant event occurring in HCC [4], the
activation of the PIK3CA pathways is a widespread occurrence ob-
served in many cancer types [47,48]. The remarkable inhibition of
these proliferative andmotogenic pathways, shown in this study (sum-
marized in Fig. 6), emphasizes the extensive function of miR-198 as
tumor suppressor, that might be not only taking part in HCC, but also
in other cancer types.
Supplementary data to this article can be found online at http://
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